- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Video
What's Happening in the Vitiligo Pipeline?
Author(s):
In this drug pipeline video, Pearl Grimes, MD, FAAD, and Seemal R. Desai, MD, FAAD discuss what's currently happening in the vitiligo pipeline including why current treatments are lacking, what's coming soon, and what it may cost.
Pearl Grimes, MD, FAAD, a Dermatology Times® board member, and Seemal R. Desai, MD, FAAD, highlight the vitiligo pipeline.
The topic of the potential treatment ruxolitinib (Opzelura; Incyte), which the FDA granted Priority Review and has a Prescription Drug User Fee Act (PDUFA) target action date is April 18, 2022, as the first FDA approved therapy for vitiligo is brought up along with the costs of this treatment. Watch the full discussion below.
Video Player is loading.
Related Videos
Addressing Ongoing Benzoyl Peroxide and Benzene Updates at AAD 2025
Expert Insights Into L'Oréal’s Voluntary Recall of Benzoyl Peroxide Products
Late-Breaking Data: Phase 3 Updates on Ruxolitinib Cream for Prurigo Nodularis
Topical Corticosteroids: Potency, Vehicles, and Best Practices
Bunick Highlights Efficacy and Safety of JAK Inhibitors
Breaking Barriers in Pediatric Vitiligo Treatment
Beyond Topicals: Surgical Solutions for Vitiligo
Promoting Open and Positive Dialogue With Families of Patients With Pediatric Vitiligo
Addressing Psychological and Social Impacts of Pediatric Vitiligo
Key Differences in Onset, Progression, Diagnosis, and Treatment of Pediatric Vitiligo
Related Content
